Skip to main content

ACHL

Stock
Health Care
Biotechnology

Performance overview

ACHL Price
Price Chart

Forward-looking statistics

Beta
0.53
Risk
59.33%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Company info

SectorHealth Care
IndustryBiotechnology
Employees226
Market cap$38.5M

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth+3.2
Credit-1.7
Liquidity+0.1
Inflation+0.8
Commodities-0.7
Interest Rates-2.0

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio-0.79
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend day—

News

Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?

Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

Zacks Investment Research (September 23, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free